Brought to you by 
Tarveda raises $30mm through Series D round
07 Mar 2017
Executive Summary
Tarveda Therapeutics Inc. (oncology) closed a $30mm Series D round from investors including new buyer Versant Ventures (lead) and returning backers New Enterprise Associates, Novo AS, NanoDimension, and Flagship Pioneering. Funds, together with money raised through the firm's $38mm Series C a year ago, will support continued development of Tarveda's Pentarin miniaturized drug conjugates including Phase I/IIa PEN221 for neuroendocrine tumors and small cell lung cancer, and preclinical PEN866 for solid tumors including colorectal, small cell lung, and sarcoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tarveda raises $30mm through Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice